Eli Lilly (LLY) Offering Possible 12.11% Return Over the Next 37 Calendar Days

This post was originally published on this site

Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $220.00 short put and a strike $200.00 long put offers a potential 12.11% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $220.00 by expiration. The full premium credit of $2.16 would be kept by the premium seller. The risk of $17.84 would be incurred if the stock dropped below the $200.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 67.44 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Eli Lilly

Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Tue, 13 Jul 2021 01:29:22 +0000
(Bloomberg) — Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resign

Eli Lilly’s Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year
Fri, 09 Jul 2021 14:45:34 +0000
Eli Lilly And Co (NYSE: LLY) has announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. In a previously published Phase 2 study, mirikizumab down-regulated several gene transcripts associated with inflamed mucosa and up-regulated gene transcripts correlated with healthy mucosa and markers of functional healing after 12 weeks. In this analysis, a set of d

Pharma Stock Roundup: GSK’s New Deal With Alector, MRK & AZN’s FDA Updates
Fri, 09 Jul 2021 12:10:12 +0000
Glaxo (GSK) to co-develop Alector’s two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study
Fri, 09 Jul 2021 10:31:00 +0000
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. These gene transcript changes, which were unique among those who responded to mirikizumab compared to placebo, were associated with mucosal healing, indicating that mirikizumab affects a distinct molecular healing pathway, compared to the spontaneous healing that occ

Biogen Stock Just Popped For An Odd Reason — Here’s Why
Thu, 08 Jul 2021 20:19:56 +0000
Biogen stock rose Thursday after the Food and Drug Administration signed off on narrower recommendations for Alzheimer’s drug Aduhelm.

Be Sociable, Share!

Related Posts